IPO-bound Aragen Life Sciences plans to invest 1.5 billion rupees ($16.05M) over the next two years to expand drug development and manufacturing. The expansion positions the firm to capture rising outsourcing demand as global pharmaceutical companies diversify supply chains. Managing Director and CEO Manmahesh Kantipudi said the company aims to scale capacity across small molecules and complex biologics ahead of its public debut.

Scaling CDMO and Discovery Operations